Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lewis D Pennington

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|March 4, 2015
A Survey of the Role of Noncovalent Sulfur Interactions in Drug DesignBrett R Beno, Kap-Sun Yeung, Michael D Bartberger, et al.
Journal of Medicinal Chemistry|June 28, 2024
Property-Based Drug Design Merits a Nobel PrizeLewis D Pennington, Matthew J Hesse, Dennis C Koester, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2012
Structure guided P1' modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer's diseaseHolger Monenschein, Daniel B Horne, Michael D Bartberger, et al.
Bioorganic & Medicinal Chemistry Letters|June 18, 2013
Hydroxyethylamine-based inhibitors of BACE1: P₁-P₃ macrocyclization can improve potency, selectivity, and cell activityLewis D Pennington, Douglas A Whittington, Michael D Bartberger, et al.
Journal of Medicinal Chemistry|March 12, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine seriesNobuko Nishimura, Mark H Norman, Longbin Liu, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1Lewis D Pennington, Kelvin K C Sham, Alexander J Pickrell, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of a Potent, Orally Active S1P1 Agonist Containing a Quinolinone CorePaul E Harrington, Michael D Croghan, Christopher Fotsch, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2011
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activityLewis D Pennington, Michael D Croghan, Kelvin K C Sham, et al.
Journal of Medicinal Chemistry|January 11, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-conceptKate S Ashton, Kristin L Andrews, Marian C Bryan, et al.
Journal of Medicinal Chemistry|January 11, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profilesDavid J St Jean, Kate S Ashton, Michael D Bartberger, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|March 4, 2015
A Survey of the Role of Noncovalent Sulfur Interactions in Drug DesignBrett R Beno, Kap-Sun Yeung, Michael D Bartberger, et al.
Journal of Medicinal Chemistry|June 28, 2024
Property-Based Drug Design Merits a Nobel PrizeLewis D Pennington, Matthew J Hesse, Dennis C Koester, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2012
Structure guided P1' modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer's diseaseHolger Monenschein, Daniel B Horne, Michael D Bartberger, et al.
Bioorganic & Medicinal Chemistry Letters|June 18, 2013
Hydroxyethylamine-based inhibitors of BACE1: P₁-P₃ macrocyclization can improve potency, selectivity, and cell activityLewis D Pennington, Douglas A Whittington, Michael D Bartberger, et al.
Journal of Medicinal Chemistry|March 12, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine seriesNobuko Nishimura, Mark H Norman, Longbin Liu, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1Lewis D Pennington, Kelvin K C Sham, Alexander J Pickrell, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of a Potent, Orally Active S1P1 Agonist Containing a Quinolinone CorePaul E Harrington, Michael D Croghan, Christopher Fotsch, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2011
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activityLewis D Pennington, Michael D Croghan, Kelvin K C Sham, et al.
Journal of Medicinal Chemistry|January 11, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-conceptKate S Ashton, Kristin L Andrews, Marian C Bryan, et al.
Journal of Medicinal Chemistry|January 11, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profilesDavid J St Jean, Kate S Ashton, Michael D Bartberger, et al.
Pageof 3